FHTX

AI MemoPost-earnings T+3

Foghorn Therapeutics

As of 2026-08-06/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FHD-909 Phase 1 execution update • 2026-11-04

Base target: $6 / p=55% prob

Biggest risk

The lead asset remains early clinical stage with no human efficacy outcome in the supplied evidence. Several meaningful pipeline milestones are targeted for 2027, while earnings surprise, analyst revisions, and market-reaction evidence are unavailable.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

FHD-909 is advancing through Phase 1, Foghorn retains multiple wholly owned oncology and immunology programs, and approximately $168 million of cash, cash equivalents, and marketable securities supports runway into the first half of 2028 [#SEC-8K-2026-08-06].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-06

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings expectation uncertainty
Pipeline IND milestones targeted for 2027
FHD-909 is advancing through Phase 1, Foghorn retains multiple wholly owned oncology and immunology programs, and approximately $168 million of cash, cash equivalents, and marketable securities supports runway into the first half of 2028 [#SEC-8K-2026-08-06].

BearKey bullets

2027 IND targets and pipeline expansion may be delayed or deprioritized.
Early-stage clinical programs may fail to demonstrate efficacy or tolerability.
No verified post-earnings surprise, guidance revision, analyst revision, or price-reaction data is available.

WatchKey bullets

FHD-909 Phase 1 execution update

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $6 (p=55%)

Target spread vs base: +55% / -50%

Scenario probabilities

Bull Target: $9 (p=20%)Base Target: $6 (p=55%)Bear Target: $3 (p=25%)

Commentary

Primary company evidence is constructive on program progress and liquidity, but the post-earnings packet lacks verified surprise, revisions, market reaction, and social coverage. The low-coverage, loose peer set warrants cautious monitoring rather than a high-conviction directional view.

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings expectation uncertainty
Pipeline IND milestones targeted for 2027

Scenarios

Bull Target (Scenario probability)

$9 / p=20% prob

Base Target (Scenario probability)

$6 / p=55% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-04
FHD-909 Phase 1 execution update
The company reported that FHD-909 dose escalation and enrollment are advancing as planned, with NSCLC as the primary target population. The supplied excerpt does not provide human efficacy data, so this is an execution catalyst rather than clinical validation [#SEC-8K-2026-08-06].
Prob 70.00% • Move 15.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Post-earnings expectation uncertainty
2026-08-10
The packet does not provide a verified revenue or EPS surprise, guidance revision, analyst revision, or post-release price reaction for the scheduled follow-up. Missing confirmation leaves near-term expectations and volatility unresolved.
Prob 60% • Move -8% • Priced-in 50%

Long-term Catalysts

Months to a year

Pipeline IND milestones targeted for 2027
2027-08-06
Foghorn is targeting 2027 INDs for selective EP300 degrader programs and a novel oral immunology/inflammation program, creating longer-duration optionality but substantial development risk [#SEC-8K-2026-08-06].
Prob 40% • Move 25% • Priced-in 15%

Risks

2027 IND targets and pipeline expansion may be delayed or deprioritized.
Early-stage clinical programs may fail to demonstrate efficacy or tolerability.
No verified post-earnings surprise, guidance revision, analyst revision, or price-reaction data is available.
Small-cap biotech event volatility and limited coverage reduce forecast confidence.

Peers

Symbol	Summary
FULC	Same-sector small-cap biotech peer selected by market capitalization; no validated clinical or operating comparison is available in the packet.
IMRX	Same-sector small-cap biotech peer selected by market capitalization; no validated clinical or operating comparison is available in the packet.
LCTX	Same-sector small-cap biotech peer selected by market capitalization; useful only as a loose market-cap reference because no clinical comparison is provided.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

Loading AI feed…

Symbol

Summary

FULC

Same-sector small-cap biotech peer selected by market capitalization; no validated clinical or operating comparison is available in the packet.

IMRX

Same-sector small-cap biotech peer selected by market capitalization; no validated clinical or operating comparison is available in the packet.

LCTX

Same-sector small-cap biotech peer selected by market capitalization; useful only as a loose market-cap reference because no clinical comparison is provided.